Coronavirus Disease 2019 (COVID-19) Impact on Digital Biomarkers Market

Pages: 27 Published: June 30, 2020 Report Code: GDHCHT132

The ongoing COVID-19 crisis has seen social distancing and lockdown measures implemented around the world, which has had widespread effects on the healthcare industry, particularly in the ways that patients and healthcare professionals can safely interact while minimizing risks of viral transmission. Remote patient monitoring and the collection of digital biomarkers by connected devices has emerged as an important approach to support patients and healthcare systems during the pandemic. This case study assesses how connected devices and digital biomarkers can be used during the COVID-19 pandemic and beyond.


This case study assesses how digital biomarkers can be used to:

Track COVID-19 patients, as well as those at risk of contracting the virus

Predict COVID-19 outbreaks

Mitigate the impact of COVID-19 on clinical trial delays during social distancing and lockdown measures

Key Highlights

Digital biomarkers are an important addition to the armamentarium of tools supporting patients and healthcare systems during the COVID-19 pandemic: Digital biomarkers such as temperature, respiratory rate, coughing, and heart rate can be easily and continuously tracked using connected devices to identify patients at risk of COVID-19, assess disease progression, and monitor symptoms. Like telemedicine, the COVID-19 pandemic could lead to the widespread use of this technology across a number of areas, particularly chronic disease.

Digital biomarkers and RPM technology could be used as a strategy to predict and prevent disease outbreaks in the future: Using digital biomarkers as a prevention strategy has potential in other infectious disease outbreaks that may occur in the future. These data can easily be tracked among the general population as an early warning system to predict hotspots, in order to rapidly prevent widespread outbreaks and transmission.

COVID-19 could be the tipping point for widespread implementation of virtual trials: As has been widely touted for telemedicine, the use of RPM in clinical trials could surge as a result of the COVID-19 crisis. The benefits of collecting patient data remotely will be realized outside of COVID-19, particularly the removal of common recruitment barriers, such as distance to trial sites and travel expenses, leading to more efficient and cost-effective clinical trials for sponsors.

Reasons to Buy

Get an overview of the opportunities that exist for the use of connected devices and digital biomarkers in remote patient monitoring during the COVID-19 pandemic and beyond.

See how digital health companies are utilizing their technology to help combat the COVID-19 crisis

Key Players

  • Medopad (now Huma)


    Oura Health

    Kinsa Health

    Scripps Research Translational Institute

Table of Contents

1. Use of Digital Biomarkers to Track COVID-19 Patients and Predict Outbreaks

Use of RPM Strategies During the Pandemic




Kinsa Health

Scripps Institute DETECT Study

2. Using Digital Biomarkers to Mitigate the Impact of COVID-19 on Clinical Trials

Impact of COVID-19 Social Distancing Measures on Clinical Trials

Adoption of Virtual Trials During the COVID-19 Crisis

Digitization of Clinical Trials Is Increasing

3. Key Takeaways

4. Appendix



Related Reports

About the Authors

About GlobalData About GlobalData

Frequently Asked Questions


Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.